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Background: Appreciating the utility of published diagnostic criteria for autoimmune pancreatitis, when compared
to the characteristics of patients clinically managed as having disease, informs and refines ongoing clinical practice.
Methods: Comparative retrospective descriptive evaluation of patients with autoimmune pancreatitis including
dedicated radiology review.
Results: 66 subjects with radiographic OR clinical features of autoimmune pancreatitis were initially identifiable
(Male: n = 50), with 55 confirmed for evaluation. The most common presentation included pain (67%), weight loss
(65%), and jaundice (62%). Diffuse enlargement of the pancreas was evident in 38%, whilst multifocal, focal, or
atrophic changes were seen in 7%, 33% and 9% respectively. 13% had no pancreatic parenchymal involvement.
Peripheral rim enhancement was seen in 23 patients (42%). Where discernible, disease was a) Sclerosing pancreatitis
and cholangitis, n = 21; b) Sclerosing cholangitis, n = 9; c) Sclerosing pancreatitis, n = 4; d) Sclerosing pancreatitis
and cholangitis with pancreatic pseudotumour, n = 7; e) Sclerosing cholangitis with hepatic pseudotumour, n = 3; f)
Sclerosing pancreatitis with pancreatic pseudotumour, n = 1. 56% of the patients had systemic manifestations and
the median serum IgG4 at diagnosis was 5.12 g/L. The Korean criteria identified most patients (82%) compared to
HISORt (55%) or the Japan Pancreas Society (56%). The majority (HISORt 60%; Japan Pancreas Society 55%; Korean
58%) met diagnostic criterion by radiological findings and elevated serum IgG4. Treatment and response did not
differ when stratified by diagnostic criteria.
Conclusion: Our descriptive and retrospective dataset confirms that in non-expert practice settings, autoimmune
pancreatitis scoring systems with a focus on radiology and serology capture most patients who are clinically felt to
have disease.
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Autoimmune pancreatitis (AIP) is the umbrella term for a
group of multi-system infiltrative and inflammatory re-
lapsing and remitting conditions, not the least limited to
pancreatic involvement, and for which clinical presenta-
tion is protean, and in which no single test is diagnostic
[1-3]. Over the last decade much interest has been shown* Correspondence: g.hirschfield@bham.ac.uk
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reproduction in any medium, provided the orin this disease, with multiple descriptions of case series
presented. This has been driven in part by increasing rec-
ognition of radiologic features of disease (such as irregular
narrowing of the main pancreatic duct and enlargement of
the pancreas), characteristic but not universal elevations of
IgG4 levels, and lymphoplasmacytic infiltrates with abun-
dant IgG4-positive plasma cells on immunostaining.
AIP is reported as more typically occurring in men (M:F
ratio of 5:1) with an average age at presentation over 60.
In Japan, where the predominant bulk of the experience of
managing this disease arose, an estimated prevalence of
2.4 per 100,000 individuals is cited [4] with this diseased. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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North America, ~2.5% of Whipple’s procedures performed
for presumed pancreatic cancer are subsequently re-
diagnosed as AIP and 20% of Whipple’s procedures for be-
nign conditions are now considered likely to be AIP [5].
Presenting as a multisystem fibro-inflammatory condition
there are various distinctive clinical, radiological, sero-
logical and pathological features, which point towards the
diagnosis, particularly since no single uniform presentation
predominates [6,7]. Frequently the diagnosis is reached in
patients with painless obstructive jaundice secondary to an
inflammatory pancreatic mass with biliary involvement.
Abdominal pain and weight loss may also be present along-
side exocrine or endocrine pancreatic insufficiency, whilst
others present with extra-pancreatic disease: sclerosing
cholecystitis, retroperitoneal fibrosis, sclerosing sialadenitis,
sclerosing dacryoadenitis, interstitial nephritis, pulmonary
interstitial fibrosis, lymphadenopathy, and pseudotumours.
Extra-pancreatic disease is now recognized in 40–90% of
patients with AIP and can be synchronous or metachro-
nous [8,9]. The exquisite sensitivity of AIP to steroid ther-
apy is a key feature in differentiating AIP from alternative
processes [10], with clear clinical response to steroids usu-
ally striking, but disease relapse not infrequent upon
steroid-withdrawal [11]. The repeated demonstration of ele-
vated IgG4 levels in patients with PSC has also raised the
spectre of a possible sub-group of patients with PSC who
might have a forme-fruste or missed diagnosis of AIP, and
steroids in this setting has been discussed widely [12,13].
Given such clinical heterogeneity there have arisen sev-
eral potential diagnostic criteria available to clinicians to
use in attempting to reach a diagnosis of AIP, and so facili-
tate early treatment. Each relies on a varied combination of
imaging findings of the pancreas and other organs, ser-
ology, pancreatic histology and response to steroids. Their
applicability in centres without dedicated pancreatic multi-
disciplinary teams remains to be clarified, along with prac-
tical utility globally remaining under reported, particularly
given that clinical and academic practice may not match.
We present our descriptive retrospective review of patient
presentation and outcomes for those with IgG4 related dis-
ease, seen across academic institutions in Toronto. In so
doing we simultaneously document a Canadian experience
of a large unselected cohort of patients with AIP, as well as
reporting the applicability of selected diagnostic criteria in
a North American setting.
Methods
We evaluated the clinical, serologic, imaging characteris-
tics and treatment response of patients given the clinical
label of AIP from 1998 to 2010 across two sites within the
Division of Gastroenterology at the University of Toronto:
University Health Network and the Centre for Advanced
Therapeutic Endoscopy and Endoscopic Oncology, St.Michael’s Hospital, Toronto, Canada. Approval for retro-
spective evaluation was obtained from University Health
Network. Given the long time frame of review, and the
changing appreciation of disease itself by clinicians, we ac-
knowledge the limitations this places on the study, and
therefore highlight the descriptive data retrieved.
A review of clinical notes (HP) and imaging studies was
undertaken, followed by analyses of clinical and treatment
outcomes. Two fellowship trained abdominal radiologists
reviewed radiological findings in consensus and confirmed
the radiological diagnosis of AIP. Imaging features reviewed
included presence or absence of intra-hepatic and extra-
hepatic biliary strictures as well as imaging abnormalities of
pancreatitis. Imaging characteristics for each of the HISORt
criteria [7], Japanese Pancreas Society [14] and Korean cri-
teria [15] were also recorded (Figures 1 and 2; Additional
file 1: Table S1). Imaging reports also included the anatomic
involvement of strictures and inflammatory pseudotumours
as originally described by Zen et al. [16]. If histological fea-
tures were available from surgical resection or core biop-
sies, in particular lymphoplasmacytic infiltrate and positive
IgG4 staining, then the diagnosis was definitive. In the ab-
sence of this, the diagnosis was also made if patients had
classical radiological features of AIP (diffusely enlarged pan-
creas with delayed enhancement and capsule-like rim;
diffusely irregular, attenuated main pancreatic duct or mul-
tiple strictures or long stricture without upstream dilata-
tion) and an elevated serum IgG4 > 2 × upper limit of
normal (ULN) (>1.72 g/L). Patients not meeting either of
these two criteria but in whom a high index of suspicion
existed (elevated serum IgG4, suggestive pancreatic im-
aging findings, other organ involvement or bile duct biopsy
with >10 IgG4 positive cells per high power field) would
undergo a trial of steroid therapy, and a positive clinical re-
sponse was considered diagnostic. Malignancy at initial
presentation was excluded in all cases. Given our selection
criteria we report on type 1 autoimmune pancreatitis; the
relative importance of type 2 autoimmune pancreatitis (so
called idiopathic duct-centric pancreatitis; those with no
IgG4 and no lymphoplasmocytic infiltrates but with
granulocyte epithelial lesions, venulitis and storioform
fibrosis) cannot be adequately addressed by our study;
in our chart survey only 4 patients were provisionally
identified that were potentially type 2 AIP and only lim-
ited clinical information on 2 was available, hence our
focus being classic AIP.
Our series represents the standard clinical practice over
the duration of the study period, with no single treatment
protocol, and many treating physicians. Treatment regi-
mens early tended to be heterogeneous, reflecting clinical
judgement and the evolving knowledge and confidence in
managing this condition. A typical treatment approach for
active disease involved the commencement of prednisone




Figure 1 Diffuse autoimmune pancreatitis. A. Axial CT image in the pancreatic parenchymal phase shows the typical enlarged, poorly
enhancing gland (arrow). Note the lack of inflammatory change around the organ which differentiates the disease from acute pancreatitis with
necrosis. B. Coronal T2 Weighted MR image demonstrates low signal intensity in the pancreas (arrow) due to the diffuse fibrosis in the gland.
C. Coronal MRCP image depicts a diffusely irregular pancreatic duct with stenosis distally in the pancreatic head (arrow). D. ERCP confirms the MR
findings including the ductal stenosis (arrow).
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response. Patients who had clinically significant biliary ob-
struction underwent therapeutic endoscopic retrograde
cholangiopancreatography (ERCP), with re-assessment of
the biliary stricture(s) on follow-up ERCPs undertaken and
intervention based on repeat cholangiography. Routine
clinical review and monitoring (including serum IgG4) were
performed and evidence of clinical, biochemical or sero-
logic disease-relapse was sought as part of clinical follow-
up. Response to steroid therapy was considered if there was
a significant improvement in liver biochemistry and/or im-
aging. Clinical remission was defined as achieving a steroid-
free state, with resolution of biliary stricture(s) (stent-free)
and previously abnormal liver biochemistry.
Results
Patient demographics and clinical presentation
A total of eighty-six patients considered as potential
AIP were first screened looking for sufficient clinical in-
formation for inclusion in the study (see study flow chart,
Figure 3). Sixty-six patients with comprehensive data had
radiographic changes OR clinical features of autoimmune
pancreatitis (Male 50, Female 16; mean age at diagnosis
58) (Table 1). Of these, eleven patients had radiological re-
ports available but no clinical data charted within our
Institutions leading to exclusion from further study. Thus,a total of fifty-five patients with a combination of clin-
ical and/or radiological features of AIP were identified,
with a predominance of men (78%) and mean age at
diagnosis of 60.
Whilst the majority of patients were Caucasian (55%),
significant numbers of non-Caucasian patients were seen:
25% South Asian, 18% East/South-East Asian, 2% African,
and 2% Middle Eastern. The mean follow-up from diagno-
sis was 22 months and the median time from symptom
onset to definitive diagnosis of AIP was 8 months (max
98 months). 10 patients underwent major surgery for sus-
pected malignancy prior to a definitive diagnosis of AIP.
The most common clinical features at presentation were
abdominal pain (67%), weight loss (65%), and obstructive
jaundice (62%) and 34 of 55 patients had 3 or more symp-
toms, including fatigue (35%), new-onset diabetes mellitus
(22%), pruritus (22%), and steatorrhoea (18%). One patient
was subsequently diagnosed with cholangiocarcinoma and
was the only patient with disease-associated mortality.
Imaging
Pre-treatment cholangiography and/or pancreatic imaging
at diagnosis were performed for all patients and a dedi-
cated radiologist reviewed all images. Fifty-four patients
(98%) had magnetic resonance cholangiopancreatography
(MRCP) while 35 patients (64%) also underwent ERCP,
AB
Figure 2 Post-therapeutic pancreatic atrophy. A. Axial contrast-
enhanced T1 weighted MR image through the pancreas depicts an
enlarged organ (arrow) with poor enhancement. Irregular beading
of the pancreatic duct can be seen even on this image. B. Follow-up
scan at the same level 12 months post steroid therapy shows
marked atrophy of the pancreas (arrow) with normal enhancement.
Total charts reviewed 
N=86
Radiological OR













Figure 3 Study design and patient evaluation.
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patients). Diffuse enlargement of the pancreas was seen in
38% of patients followed for AIP, whilst multifocal, focal,
atrophic changes were seen in 7%, 33% and 9% of patients
respectively. Thirteen percent had no pancreatic paren-
chymal involvement. Peripheral rim enhancement was
seen in 23 patients (42%). The fibro-inflammatory process
affected both the biliary tree and pancreas in the majority
of patients. Where discernible, disease was a) Sclerosing
pancreatitis and cholangitis, n = 21; b) Sclerosing cholan-
gitis, n = 9; c) Sclerosing pancreatitis, n = 4; d) Scleros-
ing pancreatitis and cholangitis with pancreatic
pseudotumour, n = 7; e) Sclerosing cholangitis with
hepatic pseudotumour, n = 3; f ) Sclerosing pancreatitis
with pancreatic pseudotumour, n = 1. Overall, intra-
hepatic (65%) and extra-hepatic (76%) biliary strictures,
and imaging abnormalities of pancreatitis (62%) were
evident in most patients.Extra-pancreatic manifestations
In keeping with the multi-systemic nature of this disease
process, 56% (n = 33) of the patients had systemic manifes-
tations, including generalized lymphadenopathy (n = 15),
renal involvement (n = 14), retroperitoneal fibrosis (n = 9),
salivary gland enlargement (n = 6), inflammatory bowel dis-
ease (IBD) (n = 4), and lung involvement (n = 2). Thirteen
patients had involvement of two or more extra-pancreatic
organs. All extra-intestinal manifestations except IBD were
made by radiological changes.Pre-treatment serology
38/55 (69%) patients had serum IgG4 levels accessible
to our review. Of these 38, 29 (81%) had IgG4 levels
twice the normal limit. The median serum IgG4 at
diagnosis for our series was 5.12 g/L (range 0.01-20.00;
normal value <0.86) falling to 1.5 g/L (n = 38; range
0.08-16.7) after treatment. An abnormality in the liver
biochemistry was seen for the majority of patients at
the time of presentation (69%): bilirubin 20 μmol/L
(median, range 5–407), ALP 246 U/L (median, range
47–1226), ALT 74 U/L (median, range 14–784), and
AST 57 U/L (median, range 13–542).
Table 1 Patient demographics
Findings Total study All criteria HISORt Japanese Korean No criteria met
Radiological features 66 - - - - -
Males (n, %) 50 (76%) - - - - -
Age (years, mean) 58 - - - - -
Clinical and radiological features 55 27 (49%) 30 (55%) 31 (56%) 45 (82%) 9 (16%)
Males (n, %) 43 (78%) 22 (81%) 25 (83%) 24 (77%) 34 (76%) 8 (%)
Age (years, mean) 60 61 61 59 60 58
Presenting symptoms
Jaundice 34 (62%) 20 (74%) 22 (73%) 20 (65%) 29 (64%) 5 (56%)
Weight loss 36 (65%) 17 (63%) 19 (63%) 19 (61%) 30 (67%) 6 (67%)
Abdominal pain 37 (67%) 18 (67%) 20 (67%) 20 (65%) 29 (64%) 7 (78%)
IgG4 (g/L, median) 5.12 5.32 5.44 5.3 4.94 7.3
IgG4 > 2 × ULN (n, %) 29 (51%) 20 (74%) 21 (70%) 24 (80%) 24 (53%) 4 (44%)
Biochemistry
Bilirubin (μmol/L*) 20 35 34 34 21 29
ALP (U/L*) 246 287 287 264 240 296
ALT (U/L*) 74 94 94 81 72 91
AST (U/L*) 57 92 92 84 58 46
Imaging Modality
CT (n, %) 49 (86%) 23 (85%) 26 (87%) 29 (84%) 40 (89%) 8 (89%)
MRCP (n, %) 54 (95%) 27 (100%) 30 (100%) 31 (100%) 44 (98%) 9 (100%)
ERCP (n, %) 35 (61%) 19 (70%) 22 (73%) 19 (61%) 28 (62%) 6 (67%)
Pancreatic parenchymal changes
Typical 24 (44%) 14 (52%) 14 (47%) 14 (45%) 20 (44%) 4 (57%)
Diffuse 5 (9%) 3 (19%) 4 (13%) 3 (10%) 4 (9%) 0 (0%)
Multifocal 23 (42%) 11 (41%) 11 (37%) 13 (42%) 18 (40%) 5 (56%)
Rim
Atypical 18 (33%) 5 (19%) 7 (23%) 9 (29%) 16 (36%) 2 (22%)
Focal 5 (9%) 4 (15%) 5 (17%) 4 (13%) 5 (11%) 0 (0%)
Atrophic
Treatment
Steroids 34 (62%) 19 (70%) 21 (70%) 22 (71%) 31 (69%) 3 (33%)
ERCP + Biliary stent 27 (49%) 15 (56%) 17 (57%) 15 (48%) 23 (51%) 4 (44%)
Steroids and biliary stent 16 (29%) 10 (37%) 12 (40%) 10 (32%) 16 (36%) 0 (0%)
*Median.
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IgG4-staining was not routinely offered by the Institu-
tional laboratories and routine tissue sampling not
performed. Histological (surgical) evidence of a lym-
phoplasmacytic infiltrate with sclerosis was available
for seven patients.
Steroid treatment and response
Thirty-four patients (62%) had sufficient ongoing clin-
ical disease to receive steroid therapy following diagno-
sis. Thirty-five (64%) patients underwent ERCP at
diagnosis of which 27 needed biliary stenting, and 16
(29%) patients went on to receive concurrent steroid
therapy and biliary stenting. Eighteen patients weretreated with steroids alone. Liver biochemistry (serum
bilirubin, alkaline phosphatase and transaminases)
normalized in ten of the eighteen patients with steroid
monotherapy, improved in 2 (fell but not to normal)
and did not change in 6 patients. Of the eleven patients
who only underwent biliary stenting, liver enzymes
normalized in 6, improved in 2 and did not change in 3
patients. In the 16 patients who received steroids and
biliary stenting, liver enzymes became normal in 11 pa-
tients and improved in 5 patients. However, stricture
resolution was achieved in only 3 of 18 patients in the
steroid only group, in 6 of the 11 who underwent bil-
iary stenting, and in 8 of 16 patients who received both
steroids and biliary stenting.
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Steroids were tapered and completely withdrawn in 20 of
the 34 patients after a median exposure to steroids of
8.1 months. Disease-relapse occurred in 15 patients after a
median of 15 month necessitating the resumption of ste-
roids and addition of an immunomodulator (azathioprine)
in 14 patients. Two patients received Rituximab [17]. Both
had steroid intolerance (infection; diabetes).
Stratification by diagnostic criteria
Published diagnostic criteria were applied retrospectively
to our cohort of clinically characterised patients, and of
the 55 patients, 30 (55%) patients met the Mayo Clinic
HISORt criteria, 31 (56%) patients the Japan Pancreas So-
ciety (JPS) criteria, and 45 (82%) patients the Korean cri-
teria. Twenty-seven patients met all three diagnostic
criteria; six patients met two diagnostic criteria (4 met JPS
and Korean and 2 met HISORt and Korean); and thirteen
patients met only one diagnostic criterion (12 met Korean
and 1 met HISORt). There were nine patients who were
included in the study that did not meet any of the diag-
nostic criteria and they are discussed later.
When stratified by diagnostic criteria the percentage of
males and mean age remained similar amongst all groups
(Table 2). There were no differences in presentation, serum
biochemistry, liver enzymes or imaging findings. Of note
the median serum IgG4 level appeared higher in those that
did not meet a diagnostic criteria, suggesting a bias in the
approach of clinicians. Similar number of patients were
treated with steroids who met the Mayo Clinic HiSORt
criteria (21/30, 70%), JPS (22/31, 72%) and Korean Criteria
(31/45, 69%)). The response to steroid therapy was seen in
similar proportions of patients who met each criterion:Table 2 Percentage of patients meeting diagnostic criteria
Diagnostic factors All criteria met HISORt (2006
n = 27 (49%) n = 30, (55%
I. Typical imaging 20 (74%) 21 (70%)
Ia. Atypical imaging 7 (26%) 9 (30%)
II. Lab IgG4 21 (81%) 23 (77%)
III. Histology 7 (30%) 8 (27%)
IV. Other organ involvement 18 (70%) 22 (73%)
V. Steroid response 14 (52%) 17 (57%)
Definite diagnosis
- III (8)
- I + II (18)
- Ia + II + V (2)
- Ia + IV + V (2HISORt 17/30 (57%), JPS 14/31 (45%), and Korean 23/45
(51%) (Table 3). Patterns of meeting diagnostic criteria
were assessed and the majority (HISORt 18/30 (60%), JPS
17/31 (55%), and Korean 26/45 (58%)) met a diagnostic
criterion with radiological findings and elevated serum
IgG4 levels (Table 4). Only seven patients had histologi-
cally proven AIP, a reflection of the clinical practice in
Toronto. The proportion of patients meeting typical radio-
logical changes was similar amongst all three diagnostic
criteria.
Patients with suspected disease
There were 9 patients who were suspected clinically to
have an IgG4 systemic disease but who did not meet a
pre-defined diagnostic criterion for AIP. Two groups were
identified: those with sclerosing cholangitis and elevated
IgG4 and those with isolated radiological changes consist-
ent with AIP. In those with radiological changes, almost
all presented with either abdominal pain (5/5), obstructive
jaundice (4/5), or weight loss (4/5) whereas these symp-
toms were not predominant in those with sclerosing chol-
angitis and an elevated IgG4. Four of the five patients in
the radiological group required ERCP and stenting with
complete resolution of symptoms. IgG4 was > 2 × ULN in
all patients with possible sclerosing cholangitis and an ele-
vated IgG4 but was not available for review for those with
radiological changes. The former group of patients with
sclerosing cholangitis and an elevated IgG4 includes
one patient who responded to steroids whilst none of
the patients in the radiological group were treated with
steroids. Histology was not obtained for any patients in
this group of suspected of AIP. Extra-pancreatic mani-
festations were not commonly seen in these patients:) Japanese (2006) Korean (2007) No criteria met
) n = 31 (56%) n = 45 (82%) n = 9 (16%)
20 (65%) 27 (60%) 4 (44%)
11 (35%) 18 (40%) 2 (22%)
26 (84%) 26 (58%) 3 (33%)
8 (26%) 8 (18%) 0 (0.0%)
21 (68%) 28 (62%) 2 (22%)
14 (45%) 23 (51%) 1 (11%)
I + II (17) I + II (18) -
Ia + II (8)
Ia + II (9) I + III (3) -
Ia + III (2)
I + III (3) I + IV (4) -
Ia + IV (2)
) Ia + III (2) I + V (5) -
Ia + V (3)
Table 3 Clinical characteristics of patients suspected of
AIP but who did not meet diagnostic criteria




Number of patients 4 5
Males (n, %) 4 (100%) 4 (80%)
Age (years, mean) 63 54
IgG4 (g/L, median) 7.3 NA
IgG4 > 2 × ULN (n, %) 4
Biochemistry
Bilirubin (μmol/L*) 11.0 (11–124) 47.0 8–217)
ALP (U/L*) 330.0 (71–1500) 204.0 (100–303)
ALT (U/L*) 62.0 (23–234) 91.0 (29–115)
AST (U/L*) 54.5 (17–229) 41.5 (21–94)
Presentation
Obstructive jaundice 1 4
Weight loss 2 4
Abdominal pain 2 5
Imaging modality
CT (n, %) 3 5
MRCP (n, %) 4 5
ERCP (n, %) 2 4
Radiological pancreatic parenchyma typical
Diffuse 0 4
Multifocal 0 0










Intrahepatic duct 4 2
Proximal extra-hepatic duct 2 4
Initial treatment
Steroids 3 0
ERCP and biliary stenting 0 4
Steroids and biliary stenting 0 0




Patel et al. BMC Gastroenterology 2013, 13:168 Page 7 of 9
http://www.biomedcentral.com/1471-230X/13/168one patient in the sclerosing cholangitis and an elevated
IgG4 group had IBD and one patient in the radiological
group had lymphadenopathy.Discussion
In this large Canadian descriptive cohort of patients with
autoimmune pancreatitis/IgG4 related disease, we de-
scribe the attributes of 55 patients with clinical disease,
carefully reviewed from a larger cohort of suspected pa-
tients. We provide confirmation of the multisystem na-
ture of disease, the critical role for high quality imaging
in reaching a diagnosis, and the response to treatment
with steroids, that mandates early diagnosis, so ensuring
good outcomes for patients. We also demonstrate the
utility of scoring systems that do not focus on histologic
evaluation, and therefore are more readily applicable
generally to all specialists in the field.
Our clinic series is representative of a general referral
practice that captures secondary and tertiary hepatobili-
ary disease in a large metropolitan city, and as a result
provides an insight into managing this condition, par-
ticularly where there is a reality, which reflects clinical
practice, to focus on radiologic evaluation rather than
histology in the diagnostic pathway. When reaching a
diagnosis of AIP clinicians are faced with an immediate
challenge of deciding what certainty is required to both
exclude malignancy and to justify steroids. A majority of
the patients presented with either elevated liver enzymes
or extra-hepatic biliary strictures and serum IgG4 levels
were greater than two times upper limit of normal in
slightly over half of the patients. It is thus highly appro-
priate to consider testing IgG4 at presentation in such
patients, as this may facilitate a more rapid diagnosis
and possibly avoid interventions such as surgery, if a
trial of steroids is contemplated. For the majority of
community gastroenterologists and hepatologists it is
not usual practice (or necessarily easy) to get tissue diag-
nosis when managing patients with presentations such
as AIP. Unlike serum IgG4 measurements, IgG4 immu-
nostaining may not be a routine immunohistochemistry
investigation. In our patient population, many patients
were successfully treated for AIP but when compared to
the various validated diagnostic criteria, not all would
have met criteria in other series. The various scoring
systems each originate from different settings, and have
an inherent academic bias. We applied these scoring sys-
tems to our cohort, and found that the Korean criterion
was of greatest utility in our cohort, with 82% of our pa-
tients meeting the proposed criteria. This reassures clini-
cians for whom histology is infrequently obtained, that it
is safe to diagnose and treat patients using an approach
heavily biased towards IgG4 elevations and imaging.
Our cohort represents a multi-ethnic community served
by a relatively few tertiary centres in Toronto, and there-
fore captures a fair cross-sectional representation of this
disease in Canada and North America. We are thus able
in this population to confirm the male predominance of
disease, with presentation most commonly in those over
Table 4 Response to treatment
Normal liver enzymes Improved liver enzymes Stricture resolution
Steroids (n = 18) 10 (56%) 2 (11%) 3 (17%)
Biliary stent (n = 11) 6 (55%) 2 (18%) 6 (55%)
Biliary stent + steroids (n = 16) 11 (69%) 5 (31%) 8 (50%)
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unusual for an autoimmune disease, and whilst the name
given to the disease suggests classic autoimmunity, there
remains a lack of good pathophysiologic understanding,
including in particular the absence of a true autoantigen.
Indeed the ethnic mix might be argued to suggest a stron-
ger common environmental stimulus for disease, than a
common genetic background.
Much has been discussed about the overlap in terms
of imaging of the biliary tree in PSC as compared to
classic AIP [18]. The incentive for pursuing such over-
lap is of course driven by the absence of PSC therapy,
as well as the frequent IgG4 elevations seen in patients
with PSC [12,13]. Of those patients in our cohort who
did not meet classic criteria for AIP, 3 had sclerosing
cholangitis with high IgG4. Their response to immuno-
suppression was not dramatic, and notably they had
limited radiologic evidence of more classic AIP. This
cautions clinicians about the initial optimism for ste-
roids in a subset of PSC patients with elevated IgG4,
and again reiterates the need for prospective research
in this area. Additionally, it favours the importance of
radiologic features of autoimmune pancreatitis in pre-
dicting outcome from steroid treatment.
Retrospective descriptive review is inevitably limited
as compared to prospective studies, but for a rare dis-
ease managed by many clinicians, across in-patient and
out-patient settings, it remains distinctly hard to be pro-
spective in ones approach. Nevertheless clinicians and
patients are in need of descriptions of disease that
match their own experience and practice, as is the case
here: our data therefore adds to the breadth of experi-
ence described for this difficult and often enigmatic dis-
ease, and highlights how patients have presented and
been managed over time, as concepts about the disease
have evolved, and clinicians have grown in their experi-
ence. Ideally specialist clinics would triage referrals and
facilitate more prospective studies to address more
closely the role of radiology over histology in diagnosing
this syndrome. Clearly our approach can’t formally val-
idate the scoring systems in use (and isn’t designed to;
nor is it designed to utilise every scoring system pres-
ently available not least because not all clinical informa-
tion was available to us, and this obstacle could not be
overcome retrospectively), but nevertheless we can
demonstrate their applied utility, which reflects the
interest of clinicians. Similarly our observations largelyreflect the type 1 AIP disease spectrum, and there will
inevitably be patients presenting with type 2 disease (al-
beit much less common) who do not adequately fit into
our description.
Autoimmune pancreatitis is notably a highly steroid
sensitive disease. In our series there was a lower than
expected steroid response to treatment. The likely ex-
planation for this, once again, reflects the real world
practice described. In settings where patients present to
a variety of clinicians, in which referral pathways are set
and potentially limited by pressure on resources, it is
more likely that patients will have a delay in diagnosis
and hence a potential impact on treatment. Additionally
without clinical confidence from treating prior patients,
clinicians may not always capture diagnosis accurately i.e.
there is a risk of over-diagnosis. Our series, and many
others, are therefore of importance in repeatedly highlight-
ing this disease once again to a general audience. We dem-
onstrate that it is important to consider autoimmune
pancreatitis as a potential diagnosis, and that the combin-
ation of prompt high quality radiologic imaging and sero-
logic studies, should allow all clinicians to make the
diagnosis, and instigate prompt intervention.
Conclusion
In conclusion we present a descriptive account of a
large cohort of patients with a rare multi-system dis-
ease, and in so doing provide clinical insight into the
management of autoimmune pancreatitis, supporting in
particular the use of a radiologic centred approach to
diagnosis and management. This parallels the reality
faced by many clinicians not able to access histology for
diagnosis, and provides ongoing support for the devel-
opment of diagnostic pathways that are adaptable to
varied clinical settings.
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